drugset
drugset / Trial / NCT03632993

Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)

NCT03632993 ↗

Phase 2 Completed 64 enrolled Endo USA Inc., a Keenova Therapeutics Company
Non-randomizedSequentialOpen-labelTreatment

Summary

The study will evaluate the safety and effectiveness of different injection techniques of Collagenase Clostridium Histolyticum (CCH) for the treatment of adult women with mild, moderate or severe Edematous Fibrosclerotic Panniculopathy (commonly known as Cellulite).

Timeline

Start
2018-09-18
Primary completion
2019-01-24
Completion
2019-01-24

Drugs

EvaluationDrugModalityDoseRoute
Comparator Collagenase Clostridium Histolyticum Protein / enzyme biologic 1.68 mg Subcutaneous

Indications

No indication recorded.